The FY24 Defense Appropriations Act is anticipated to provide funding for the Melanoma Research Program to support innovative, high-impact melanoma research.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
